Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+immune cells in clinical colorectal cancer

被引:25
作者
Grimm, Martin [1 ]
Kim, Mia [2 ]
Rosenwald, Andreas [3 ]
von Randen, Burkhard [2 ]
Tsaur, Igor [4 ]
Meier, Eva [1 ]
Heemann, Uwe [5 ]
Germer, Christoph-Thomas [2 ]
Gasser, Martin [2 ]
Waaga-Gasser, Ana Maria [1 ]
机构
[1] Univ Wurzburg, Dept Surg Mol Oncol & Immunol 1, D-97080 Wurzburg, Germany
[2] Univ Wurzburg, Dept Surg 1, D-97080 Wurzburg, Germany
[3] Univ Wurzburg, Inst Pathol, D-97080 Wurzburg, Germany
[4] Goethe Univ Frankfurt, Dept Urol, Frankfurt, Germany
[5] Univ Munich, Dept Nephrol, Klinikum Rechts Isar, Munich, Germany
关键词
Tumour escape mechanisms; Death receptor expression; Apoptosis; Colorectal carcinoma; NECROSIS-FACTOR; DEATH RECEPTORS; IN-VIVO; FAS COUNTERATTACK; IMMUNE EVASION; T-CELLS; LIGAND; LYMPHOCYTES; MECHANISMS; CARCINOMA;
D O I
10.1016/j.ejca.2010.05.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Expression of apoptosis-related proteins on tumour cells has been shown in several experimental models to be an efficient mechanism for a counterattack against host anti-tumour immune responses in solid tumours. Here we provide a clinical evidence for such a tumour immune escape mechanism by demonstrating tumour to T cell-directed death receptor signalling (TRAIL/TRAIL-Receptor (TRAIL-R)) in colorectal cancer (CRC). In a series of patients with CRC and completed 5-year follow up, we investigated apoptosis and expression levels of apoptosis-related proteins. Gene and protein profiles in the tumours demonstrated intratumoural upregulated gene expression for Fas, Fas-L, TRAIL, TRAIL-R and TNF-alpha (RT-qPCR). Levels of terminaldeoxynucleotidyl transferase-mediated deoxyuridinetriphosphate nick-end labelling (TUNEL)-positive events were positively correlated with TRAIL-R1-expression on tumour infiltrating immune cells. Among the immune cells, preferentially CD8+ T cells were found to express TRAIL-R1 while serial immunostaining in the same patient tumours showed abundant apoptotic (TUNEL-positive) immune cells. In conclusion, our results in tumour samples from CRC patients suggest TRAIL-R1-mediated apoptotic depletion of infiltrating immune cells (CD8+) in response to TRAIL expression by the tumour itself. This supports the notion of an efficient escape from tumour immune response and thus evasion from the attack of activated CD8+ T cells. These findings may enhance our understanding of tumour progression in CRC and might be helpful for the development of TRAIL and its death receptor-based therapy. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2314 / 2323
页数:10
相关论文
共 28 条
[1]
INSITU END-LABELING DETECTS DNA STRAND BREAKS IN APOPTOSIS AND OTHER PHYSIOLOGICAL AND PATHOLOGICAL STATES [J].
ANSARI, B ;
COATES, PJ ;
GREENSTEIN, BD ;
HALL, PA .
JOURNAL OF PATHOLOGY, 1993, 170 (01) :1-8
[2]
Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[3]
Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[4]
Tumor necrosis factor or tumor promoting factor? [J].
Balkwill, F .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :135-141
[5]
Bennett MW, 1998, J IMMUNOL, V160, P5669
[6]
Compton CC, 2000, ARCH PATHOL LAB MED, V124, P979
[7]
Modulation of death receptors by cancer therapeutic agents [J].
Elrod, Heath A. ;
Sun, Shi-Yong .
CANCER BIOLOGY & THERAPY, 2008, 7 (02) :163-173
[8]
IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION [J].
GAVRIELI, Y ;
SHERMAN, Y ;
BENSASSON, SA .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :493-501
[9]
Giovarelli M, 1999, J IMMUNOL, V163, P4886
[10]
Greene Frederick L, 2003, Semin Surg Oncol, V21, P23, DOI 10.1002/ssu.10018